Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/223052
Title: | Bicistronic CAR-T Cell against BCMA and CD229 effectively controls myeloma even when BCMA expression is limited. |
Author: | Rodríguez Lobato, Luis Gerardo Cardús Granell, Oriol Mañé Pujol, Joan Battram, Anthony M. Vaqué Salsench, Sergi Carpio Marmol, Judit Pérez Amill, Lorena Calderón, Hugo Martín Antonio, Araceli Beatriz Oliver Caldés, Aina Lozano Garcia, Ester Moreno Fajardo, David Fernando Ortiz Maldonado, Valentín Salas Gay, María Queralt Daniel Bisbe, Anna de Tovar Gomis, Natalia Cibeira López, M. Teresa Rosiñol Dachs, Laura Bladé, J. (Joan) Juan, Manel Urbano Ispizua, Álvaro Engel Rocamora, Pablo Fernández de Larrea Rodríguez, Carlos José |
Keywords: | Mieloma múltiple Teràpia cel·lular Multiple myeloma T cells |
Issue Date: | 2-Sep-2025 |
Publisher: | American Association for Cancer Research |
Abstract: | Anti-BCMA CAR-T cell therapy has revolutionized the prognosis of relapsed / refractory multiple myeloma patients. Regrettably, despite unprecedented overall response rates achieved with this approach, most patients eventually relapse. One of the primary reasons for this is the complete loss or reduced expression of BCMA on the malignant plasma cell surface. Consequently, new therapeutic targets are under investigation. Another potential therapeutic approach involves the use of CAR-T cells targeting two tumor antigens. In this study, we developed and validated a monospecific CAR targeting CD229, which was effective in in vitro and in vivo NSG mouse models with both homogeneous and heterogeneous BCMA expression. Additionally, we created a bicistronic CAR-T cell targeting both CD229 and BCMA, which demonstrated efficacy in models with homogeneous BCMA expression, in heterogeneous models featuring small clonal populations with biallelic BCMA deletion, and in cases with reduced BCMA expression both in vivo and in vitro. Regarding "on-target off-tumor toxicity," no fratricide was observed among CAR-T cells, but there was a limited elimination of non-activated T-cells. The immune pressure exerted by anti-CD229 CAR-T cells led to the loss of the CD229 antigen expression in some instances. In summary, this work underscores the potential utility of CD229 alone or in combination with BCMA, as an immunotherapeutic target in multiple myeloma, especially in cases marked by diminished or absent BCMA expression. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1158/2326-6066.CIR-24-1313 |
It is part of: | Cancer Immunology Research, 2025, vol. 13, num. 9, p. 1374-1390 |
URI: | https://hdl.handle.net/2445/223052 |
Related resource: | https://doi.org/10.1158/2326-6066.CIR-24-1313 |
ISSN: | 2326-6074 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Manuscript CD229 CART CIR FINAL.pdf | 5.77 MB | Adobe PDF | View/Open Request a copy |
Document embargat fins el
2-9-2026
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.